Rising Infectious Diseases Fueling Growth In The Anthrax Vaccine Market: A Key Factor Shaping the Future of the Anthrax Vaccine Market in 2025

What Are the Projections for the Size and Growth Rate of the Anthrax Vaccine Market?
The market for the anthrax vaccine has experienced a significant expansion in the past few years. Its market size is projected to increase from $11.27 billion in 2024 to $11.88 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.4%. The historical increase can be linked to factors such as worries about biological warfare, military requirements, occurrences of anthrax outbreaks, readiness of public health, and biodefense initiatives.

The market for anthrax vaccines is projected to experience robust expansion in the coming years, reaching a size of $14.5 billion by 2029, with a 5.1% compound annual growth rate (CAGR). Factors propelling this anticipated growth over the forecast period are global security issues, emerging challenges, governmental purchasing schemes, and readiness for pandemics. Technological advancements, improved vaccine accessibility in developing nations, a focus on developing future generation vaccines, enlarged government reserves, and joint research initiatives represent the key trends during this forecast period.

What Factors Are Fueling Growth in the Anthrax Vaccine Market?
The growth of the anthrax vaccine market is anticipated to be driven by the increasing instances of infectious diseases. These diseases are marked by illnesses that stem from pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which have the potential to spread among people either directly or indirectly. The severity of the symptoms can vary from mild to extreme, sometimes leading to death, contingent on the host's immune response and the pathogen involved. Factors contributing to the rise of these diseases include shifts in global demographics, urbanization, alterations in environmental and land use, and changes in human behavior. The anthrax vaccine, chiefly used in preventing anthrax, is now being researched for its potential wider use in the combat against other infectious diseases, exploring its immunogenic qualities and adaptability. The Council on Foreign Relations, a US-based nonprofit organization, reported in February 2023 that about 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of known infectious diseases were of zoonotic origin. Zoonoses are responsible globally for 2.7 million deaths annually and 2.5 billion incidences of human disease. Hence, the escalating instances of diseases are stimulating the growth of the anthrax vaccine market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Which Businesses Are at the Forefront of Anthrax Vaccine Market Development?
Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

What Are the Latest Innovations in the Anthrax Vaccine Market?
Prominent players in the anthrax vaccine market are concentrating on the invention of novel products and the attainment of FDA approval to assure their vaccines are safe, effective, and accessible to those potentially exposed to anthrax. The confirmation from the FDA means that the vaccine has undergone comprehensive clinical trial testing and been verified as safe for public consumption, thereby safeguarding individuals from likely undesirable consequences. For example, Emergent BioSolutions Inc., a biopharmaceutical firm located in the United States, earned approval for CYFENDUS(Anthrax Vaccine Adsorbed, Adjuvanted), earlier referred to as AV7909, from the U.S. Food and Drug Administration (FDA) in July 2023. This approval hinged on details from a Phase 2 study assessing Cyfendus's ability not to interfere with antibacterial drugs and Phase 3 clinical trial examining its immunogenicity and safety in comparison to BioThrax, the earlier anthrax vaccine. Moreover, the creation of safer and highly efficient adjuvants is crucial to overcome issues related to reactogenicity and improve the overall effectiveness of anthrax vaccines.

How Is the Anthrax Vaccine Market Segmented?
The anthrax vaccine market covered in this report is segmented -

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Where Is the Anthrax Vaccine Market Growth Most Prominent?
North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Anthrax Vaccine Global Market Report?

- Market Size Analysis: Analyze the Anthrax Vaccine Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Anthrax Vaccine Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Anthrax Vaccine Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Anthrax Vaccine Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15511

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.